Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.26 USD | -4.00% |
|
-5.63% | -13.99% |
Jun. 14 | Raymond James Adjusts Price Target on Xencor to $40 From $58, Maintains Strong Buy Rating | MT |
Jun. 14 | BMO Capital Adjusts Xencor's Price Target to $32 From $34, Keeps Outperform Rating | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.99% | 1.13B | C+ | ||
+16.44% | 122B | B+ | ||
+18.94% | 113B | B+ | ||
+18.89% | 26.22B | B | ||
-25.37% | 19.01B | B+ | ||
-20.46% | 15.71B | - | A- | |
-20.20% | 15.22B | B | ||
-47.37% | 14.72B | A- | ||
+59.91% | 14.58B | C+ | ||
+4.35% | 13.84B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XNCR Stock
- Ratings Xencor, Inc.